Steven Z Pavletic
Overview
Explore the profile of Steven Z Pavletic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
205
Citations
6159
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schulz E, Pirsl F, McGraw K, Nousome D, Liu Y, Goklemez S, et al.
Bone Marrow Transplant
. 2025 Mar;
PMID: 40057632
No abstract available.
2.
Jorgensen J, Joe G, Jimenez-Silva R, Ho P, Dunigan T, Mitchell S, et al.
Transplant Cell Ther
. 2025 Mar;
PMID: 40054697
Background: Deficits in motor performance and functional abilities represent a severe complication for individuals with steroid refractory chronic graft versus host disease (cGVHD) and is associated with decreased survival and...
3.
Schoemans H, Stienissen E, Goris K, Stewart S, Cowden M, Arnahoutova K, et al.
Lancet Haematol
. 2025 Mar;
12(3):e214-e223.
PMID: 40044256
Graft-versus-host disease (GVHD) is a complication of hematopoietic cell transplantation (HCT) that has a low chance of complete remission and a substantial effect on morbidity and mortality. To better understand...
4.
Jurdi N, Blazar B, Pavletic S
Transplantation
. 2025 Feb;
PMID: 39915926
Chronic graft-versus-host disease (cGVHD) is an immune-mediated, heterogeneous, multiorgan complication affecting allogeneic hematopoietic cell transplantation recipients, leading to increased morbidity, mortality, and decline in health-related quality-of-life. Advances in understanding the...
5.
Mina A, McGraw K, Cunningham L, Kim N, Jen E, Calvo K, et al.
Blood Adv
. 2025 Jan;
9(5):1095-1104.
PMID: 39786387
Myelodysplastic syndromes/neoplasms (MDSs) are heterogeneous stem cell malignancies characterized by poor prognosis and no curative therapies outside of allogeneic hematopoietic stem cell transplantation. Despite some recent approvals by the US...
6.
McGraw K, Aplan P, Pavletic S
Semin Hematol
. 2024 Dec;
61(6):345-347.
PMID: 39674608
No abstract available.
7.
Simunic M, McGraw K, Pavletic S, Rashidi A
Semin Hematol
. 2024 Nov;
61(6):442-448.
PMID: 39551677
The intestinal microbiome has been mechanistically linked with health and many disease processes. Cancer is no exception. Both in solid tumors and hematologic malignancies, there is increasing evidence supporting the...
8.
9.
Schulz E, Pavletic S, Mina A
Semin Hematol
. 2024 Nov;
61(6):420-430.
PMID: 39523201
Myelodysplastic syndromes/neoplasms (MDS) and related diseases are highly heterogeneous myeloid stem cell cancers that predominantly affect the elderly. The only curative treatment is allogeneic hematopoietic cell transplantation (HCT). Given the...
10.
Zhao A, Holtzman N, Golubic M, Pavletic S
Transplant Cell Ther
. 2024 Oct;
30(9S):S597-S609.
PMID: 39370239
Although lifestyle interventions have shown promise in oncology and for cancer survivorship, their potential to improve outcomes in allogeneic hematopoietic cell transplantation (allo-HCT) and chronic graft-versus-host disease (cGVHD) patients remains...